The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I trial of riluzole and sorafenib in patients with advanced solid tumors and melanoma.
Janice M. Mehnert
Research Funding - Bayer/Onyx
Neha Semlani
No relevant relationships to disclose
Yvonne Wen
No relevant relationships to disclose
Antoinette R. Tan
Research Funding - Bayer/Onyx
Rebecca Anne Moss
No relevant relationships to disclose
Shari Adams
No relevant relationships to disclose
Mark N. Stein
No relevant relationships to disclose
Mikel Ross
No relevant relationships to disclose
Michael P. Kane
No relevant relationships to disclose
Darlene Gibbon
No relevant relationships to disclose
John Joseph Wright
No relevant relationships to disclose
Joseph Aisner
No relevant relationships to disclose
Suzie Chen
No relevant relationships to disclose
James S Goydos
No relevant relationships to disclose